
M Di Nisio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/445427/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to: â€~Rational use of tocilizumab in COVID-19' by Jain and Sharma. Annals of the Rheumatic Diseases, 2022, 81, e215-e215.	0.5	0
2	Response to: â€~Correspondence on â€~Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study' by Potere <i>et al'</i> by Buckley. Annals of the Rheumatic Diseases, 2022, 81, e195-e195.	0.5	11
3	Extended venous thromboprophylaxis in patients hospitalized for acute ischemic stroke: A systematic review and meta-analysis. European Journal of Internal Medicine, 2022, 95, 80-86.	1.0	3
4	Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2022, 20, 661-670.	1.9	11
5	Targeting the NLRP3 inflammasome in cardiovascular diseases. , 2022, 236, 108053.		71
6	Management of upper extremity deep vein thrombosis: an updated review of the literature. Minerva Medica, 2022, 112, .	0.3	4
7	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Advances, 2022, 6, 3569-3578.	2.5	19
8	Unanswered questions in cancerâ€associated thrombosis. British Journal of Haematology, 2022, 198, 812-825.	1.2	11
9	High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis. Internal and Emergency Medicine, 2022, 17, 1817-1825.	1.0	8
10	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. European Journal of Internal Medicine, 2021, 83, 34-38.	1.0	25
11	Clinical history of cancerâ€associated splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis, 2021, 19, 983-991.	1.9	12
12	Effects of body composition on the procoagulant imbalance in obese patients. Journal of Thrombosis and Thrombolysis, 2021, 51, 1036-1042.	1.0	0
13	Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood, 2021, 137, 1233-1240.	0.6	42
14	Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study. Thrombosis Update, 2021, 2, 100030.	0.4	3
15	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974.	2.5	431
16	Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2021, 121, 867-876.	1.8	28
17	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. Cancer Treatment Reviews, 2021, 96, 102190.	3.4	14
18	Risk Assessment Models for Thrombosis and Anticoagulant-Related Bleeding in Ambulatory Cancer Patients. Seminars in Thrombosis and Hemostasis, 2021, 47, 972-981.	1.5	6

#	Article	IF	CITATIONS
19	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 2618-2628.	1.9	12
20	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of Thrombosis and Haemostasis, 2021, 19, 3008-3017.	1.9	10
21	Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	12
22	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 2791-2800.	1.9	7
23	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. Blood, 2021, 138, 671-671.	0.6	1
24	Prediction of venous thromboembolism in patients with lower-limb immobilization. EClinicalMedicine, 2020, 21, 100285.	3.2	0
25	Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. International Journal of Infectious Diseases, 2020, 100, 421-424.	1.5	28
26	Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2400-2407.	1.9	16
27	Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thrombosis Research, 2020, 196, 67-74.	0.8	178
28	Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Cancers, 2020, 12, 2493.	1.7	14
29	Effects of Obesity and Thrombophilia on the Risk of Abortion in Women Undergoing In Vitro Fertilization. Frontiers in Endocrinology, 2020, 11, 594867.	1.5	7
30	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1661-1671.	1.9	10
31	Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsisâ€associated coagulopathy: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1618-1625.	1.9	32
32	Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Critical Care, 2020, 24, 389.	2.5	158
33	Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis. Journal of Clinical Medicine, 2020, 9, 2069.	1.0	30
34	Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life. The Cochrane Library, 2020, 2020, CD012277.	1.5	46
35	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	1.9	60
36	Anticoagulant therapy for splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 1562-1568.	1.9	60

#	Article	IF	CITATIONS
37	The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism. Thrombosis Research, 2019, 181, 59-63.	0.8	5
38	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A postâ€hoc analysis of the Hokusaiâ€VTE Cancer study. Journal of Thrombosis and Haemostasis, 2019, 17, 1866-1874.	1.9	42
39	<p>Splanchnic Vein Thrombosis: Current Perspectives</p> . Vascular Health and Risk Management, 2019, Volume 15, 449-461.	1.0	74
40	Treatment of venous thromboembolism with tinzaparin in oncological patients. Minerva Medica, 2019, 110, 251-258.	0.3	6
41	Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. Journal of Clinical Oncology, 2019, 37, 1713-1720.	0.8	90
42	Proximal and isolated distal deep vein thrombosis and Wells score accuracy in hospitalized patients. Internal and Emergency Medicine, 2019, 14, 901-902.	1.0	0
43	Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. Journal of Thrombosis and Thrombolysis, 2019, 48, 125-133.	1.0	18
44	Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. Thrombosis Research, 2019, 176, 79-84.	0.8	8
45	The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica, 2019, 104, 1277-1287.	1.7	197
46	Treatment for superficial thrombophlebitis of the leg. The Cochrane Library, 2018, 2018, CD004982.	1.5	37
47	Non-O blood group and outcomes of in vitro fertilization. Journal of Assisted Reproduction and Genetics, 2018, 35, 1289-1294.	1.2	9
48	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. New England Journal of Medicine, 2018, 378, 615-624.	13.9	1,237
49	Effects of multiple inherited and acquired thrombophilia on outcomes of in-vitro fertilization. Thrombosis Research, 2018, 167, 26-31.	0.8	11
50	Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness. Thrombosis Research, 2018, 169, 44-49.	0.8	8
51	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thrombosis and Haemostasis, 2018, 118, 1439-1449.	1.8	154
52	Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2018, 16, 1336-1346.	1.9	23
53	Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2018, 118, 1270-1278.	1.8	15
54	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematology,the, 2018, 5, e289-e298.	2.2	219

#	Article	IF	CITATIONS
55	Diagnosis of overt and non-overt disseminated intravascular coagulation: A survey among experts and a call for action from the ISTH. Thrombosis Research, 2017, 152, 74-76.	0.8	4
56	The diagnostic management of upper extremity deep vein thrombosis: A review of the literature. Thrombosis Research, 2017, 156, 54-59.	0.8	37
57	Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica, 2017, 102, 1494-1501.	1.7	164
58	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open, 2017, 7, e015562.	0.8	14
59	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open, 2017, 7, e017046.	0.8	230
60	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2017, 167, 410.	2.0	96
61	Is standâ€ e lone Dâ€ d imer testing safe to rule out acute pulmonary embolism?. Journal of Thrombosis and Haemostasis, 2017, 15, 323-328.	1.9	16
62	Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thrombosis and Haemostasis, 2017, 117, 784-793.	1.8	35
63	Incidental venous thromboembolism: is anticoagulation indicated?. Hematology American Society of Hematology Education Program, 2017, 2017, 121-127.	0.9	52
64	An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients. Blood, 2017, 130, 626-626.	0.6	4
65	Current management strategies and longâ€ŧerm clinical outcomes of upper extremity venous thrombosis. Journal of Thrombosis and Haemostasis, 2016, 14, 973-981.	1.9	46
66	Deep vein thrombosis and pulmonary embolism. Lancet, The, 2016, 388, 3060-3073.	6.3	572
67	ADAMTSâ€13 and von Willebrand factor predict venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2016, 14, 306-315.	1.9	60
68	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. The Cochrane Library, 2016, 12, CD008500.	1.5	70
69	Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review. Thrombosis Research, 2016, 140, S81-S88.	0.8	31
70	Incidental pulmonary embolism in cancer patients: Interobserver agreement on the diagnosis and extent with a focus on distal clots. Thrombosis Research, 2016, 147, 46-51.	0.8	11
71	Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thrombosis Research, 2016, 145, 46-50.	0.8	16
72	A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients. Thrombosis Research, 2016, 148, 59-62.	0.8	15

#	Article	lF	CITATIONS
73	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. Thrombosis and Haemostasis, 2016, 116, 739-746.	1.8	58
74	Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thrombosis and Haemostasis, 2016, 115, 424-432.	1.8	45
75	Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy. Drugs, 2016, 76, 331-341.	4.9	6
76	Edoxaban for treatment of venous thromboembolism in patients with cancer. Thrombosis and Haemostasis, 2015, 114, 1268-1276.	1.8	79
77	Treatment for superficial infusion thrombophlebitis of the upper extremity. The Cochrane Library, 2015, , CD011015.	1.5	10
78	Management of disseminated intravascular coagulation: A survey of the International Society on Thrombosis and Haemostasis. Thrombosis Research, 2015, 136, 239-242.	0.8	21
79	Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery. The Cochrane Library, 2015, , CD009658.	1.5	19
80	Whole-Arm Ultrasound for Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients. JAMA Internal Medicine, 2015, 175, 1871.	2.6	0
81	Dementia in patients with atrial fibrillation and the value of the <scp>H</scp> achinski ischemic score. Geriatrics and Gerontology International, 2015, 15, 770-777.	0.7	23
82	Management of cancerâ€associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 671-675.	1.9	55
83	Cannabinoids for Medical Use. JAMA - Journal of the American Medical Association, 2015, 313, 2456.	3.8	1,629
84	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1474.	2.6	180
85	Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 880-883.	1.9	96
86	Rivaroxaban for Cancer-associated Cardiac Thrombosis. American Journal of Medicine, 2015, 128, e43-e44.	0.6	7
87	24 weeks of Pilates-aerobic and educative training to improve body fat mass in elderly Serbian women. Clinical Interventions in Aging, 2014, 9, 741.	1.3	4
88	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2014, , CD008500.		38
89	Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 1746-1749.	1.9	36
90	Treatment of Lower Extremity Superficial Thrombophlebitis. JAMA - Journal of the American Medical Association, 2014, 311, 729.	3.8	11

#	Article	IF	CITATIONS
91	Plasma concentrations of D-dimer and outcome of in vitro fertilization. Journal of Ovarian Research, 2014, 7, 58.	1.3	12
92	Cancer-associated unsuspected pulmonary embolism. Thrombosis Research, 2014, 133, S172-S178.	0.8	65
93	Heart Failure and Cognitive Impairment: Relationships with Mortality. American Journal of Medicine, 2013, 126, e15.	0.6	0
94	Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. Journal of Thrombosis and Haemostasis, 2013, 11, 761-767.	1.9	366
95	Treatment for superficial thrombophlebitis of the leg. The Cochrane Library, 2013, , CD004982.	1.5	89
96	Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux. Drug Design, Development and Therapy, 2013, 7, 973.	2.0	5
97	Treatment for superficial thrombophlebitis of the leg. , 2012, , CD004982.		13
98	Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2012, 129, e177-e184.	0.8	119
99	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2012, , CD008500.		124
100	Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer. Journal of Clinical Oncology, 2011, 29, 2071-2076.	0.8	137
101	Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood, 2011, 118, 2670-2678.	0.6	83
102	Obesity, Poor Muscle Strength, and Venous Thromboembolism in Older Persons: The InCHIANTI Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 320-325.	1.7	16
103	Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thrombosis and Haemostasis, 2010, 104, 1049-1054.	1.8	87
104	Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. Journal of Thrombosis and Haemostasis, 2010, 8, 684-692.	1.9	154
105	Treatment for superficial thrombophlebitis of the leg. , 2007, , CD004982.		12
106	Treatment for superficial thrombophlebitis of the leg. , 2007, , CD004982.		22
107	Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. Journal of Thrombosis and Haemostasis, 2007, 5, 296-304.	1.9	391
108	Endothelial damage of the internal carotid artery after chemoradiotherapy of the neck for a Hodgkin lymphoma. Thrombosis and Haemostasis, 2007, 97, 315-6.	1.8	3

#	Article	IF	CITATIONS
109	Decision analysis for cancer screening in idiopathic venous thromboembolism. Journal of Thrombosis and Haemostasis, 2005, 3, 2391-2396.	1.9	60
110	Plasma cytokine and P-selectin levels in advanced malignancy. Cancer, 2005, 104, 2275-2281.	2.0	13
111	Direct Thrombin Inhibitors. New England Journal of Medicine, 2005, 353, 1028-1040.	13.9	601
112	Antithrombotic therapy and cancer. Current Opinion in Hematology, 2004, 11, 187-191.	1.2	5